Alvotech and STADA Launch Hukyndra (biosimilar, adalimumab) in Switzerland

Shots:

Alvotech & STADA launch Hukyndra, a biosimilar to Humira (adalimumab) & marketed by Spirig HealthCare AG, STADA’s subsidiary in Switzerland
Hukyndra is a high-concentration, low-volume, citrate-free formulation that is available in 80mg/0.8mL & 40mg/0.4mL in a self-administration safety device & 40mg/0.4mL in a pre-filled auto-inject pen. Under the collaboration with STADA, Alvotech’s strength will use for biosimilars development & manufacturing platform to broaden patient access to cost-effective biologics across the EU
Hukyndra was approved in the EU & other countries as Simlandi & is under review in multiple countries, incl. the US. The collaboration b/w Alvotech & STADA in the EU includes Hukyndra & 6 biosimilar candidates across autoimmunity & other indications

Ref: Globenewswire | Image: Alvotech